Reply: A positive step toward cost-effective and accessible HCC detection awaits further validation.
作者信息
El-Serag Hashem B, Jin Qingchun, Nabihah Tayob
机构信息
Section of Gastroenterology and Hepatology, Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA.
Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
出版信息
Hepatology. 2025 Mar 1;81(3):E110-E111. doi: 10.1097/HEP.0000000000001207. Epub 2024 Dec 18.
Abstract
摘要
相似文献
1
Reply: A positive step toward cost-effective and accessible HCC detection awaits further validation.回复：朝着具有成本效益且可及的肝癌检测迈出的积极一步有待进一步验证。
Hepatology. 2025 Mar 1;81(3):E110-E111. doi: 10.1097/HEP.0000000000001207. Epub 2024 Dec 18.
2
Letter to the Editor: A positive step toward cost-effective and accessible HCC detection awaits further validation.致编辑的信：朝着具有成本效益且可及的肝癌检测迈出的积极一步有待进一步验证。
Hepatology. 2025 Mar 1;81(3):E108-E109. doi: 10.1097/HEP.0000000000001196. Epub 2024 Dec 17.
3
Reply to: "A good step toward low-cost prognostication of liver-related outcome awaits more validation".
J Hepatol. 2022 Sep;77(3):889-890. doi: 10.1016/j.jhep.2022.05.034. Epub 2022 Jun 9.
4
Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.超声造影使用声诺维®（六氟化硫微泡）与对比增强计算机断层扫描和对比增强磁共振成像在局灶性肝脏病变的特征描述和肝转移检测中的比较：系统评价和成本效益分析。
Health Technol Assess. 2013 Apr;17(16):1-243. doi: 10.3310/hta17160.
5
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.肝细胞癌肝硬化监测：系统评价与经济分析
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
6
Evaluating the combined diagnostic power of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II for hepatocellular carcinoma.评估甲胎蛋白和维生素K缺乏或拮抗剂-II诱导蛋白对肝细胞癌的联合诊断效能。
J Gastrointest Oncol. 2025 Jun 30;16(3):1157-1175. doi: 10.21037/jgo-2024-863. Epub 2025 Jun 27.
7
Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.肝细胞癌肝切除术后晚期复发个体化预测模型（POLAR-HCC）的开发与验证：一项多中心研究
Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18213-9.
8
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy.意大利人工智能（AI）在早期检测有肝细胞癌风险的肝硬化患者肝脏病变中的成本效益分析。
J Med Econ. 2025 Dec;28(1):1023-1036. doi: 10.1080/13696998.2025.2525006. Epub 2025 Jul 11.
9
Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma.建立并验证一个用于诊断 AFP 阴性肝细胞癌的模型。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11295-11308. doi: 10.1007/s00432-023-04997-4. Epub 2023 Jun 27.
10
Single-cell RNA sequencing reveals a B cell-related immunosuppressive landscape and a potential suppressor in hepatocellular carcinoma.单细胞RNA测序揭示了肝细胞癌中与B细胞相关的免疫抑制格局及一种潜在抑制因子。
J Transl Med. 2025 Jul 28;23(1):847. doi: 10.1186/s12967-025-06869-6.
本文引用的文献
1
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.在检测肝癌方面，HES V2.0优于GALAD：美国一项3期生物标志物研究。
Hepatology. 2025 Feb 1;81(2):465-475. doi: 10.1097/HEP.0000000000000953. Epub 2024 Jun 19.
2
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis.肝硬化患者肝细胞癌风险分层模型。
Clin Gastroenterol Hepatol. 2023 Dec;21(13):3296-3304.e3. doi: 10.1016/j.cgh.2023.04.019. Epub 2023 Apr 30.
Zotero 插件